PF 750Selective FAAH inhibitor CAS# 959151-50-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 959151-50-9 | SDF | Download SDF |
| PubChem ID | 25154868 | Appearance | Powder |
| Formula | C22H23N3O | M.Wt | 345.44 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | ||
| Chemical Name | N-phenyl-4-(quinolin-3-ylmethyl)piperidine-1-carboxamide | ||
| SMILES | C1CN(CCC1CC2=CC3=CC=CC=C3N=C2)C(=O)NC4=CC=CC=C4 | ||
| Standard InChIKey | BIODYGOZWZNCAG-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C22H23N3O/c26-22(24-20-7-2-1-3-8-20)25-12-10-17(11-13-25)14-18-15-19-6-4-5-9-21(19)23-16-18/h1-9,15-17H,10-14H2,(H,24,26) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Irreversible fatty acid amide hydrolase (FAAH) inhibitor (IC50 = 16.2 nM) that displays no activity at a range of other serine hydrolases. Selectively inhibits FAAH within the central nervous system. Orally active. |
PF 750 Dilution Calculator
PF 750 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.8949 mL | 14.4743 mL | 28.9486 mL | 57.8972 mL | 72.3715 mL |
| 5 mM | 0.579 mL | 2.8949 mL | 5.7897 mL | 11.5794 mL | 14.4743 mL |
| 10 mM | 0.2895 mL | 1.4474 mL | 2.8949 mL | 5.7897 mL | 7.2371 mL |
| 50 mM | 0.0579 mL | 0.2895 mL | 0.579 mL | 1.1579 mL | 1.4474 mL |
| 100 mM | 0.0289 mL | 0.1447 mL | 0.2895 mL | 0.579 mL | 0.7237 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- A922500
Catalog No.:BCC2333
CAS No.:959122-11-3
- 2-Benzoylacetanilide
Catalog No.:BCC8560
CAS No.:959-66-0
- Sotalol hydrochloride
Catalog No.:BCC5165
CAS No.:959-24-0
- 12-Hydroxy-8(17),13-labdadien-16,15-olide
Catalog No.:BCN1298
CAS No.:958885-86-4
- GSK1059615
Catalog No.:BCC4984
CAS No.:958852-01-2
- SID 26681509
Catalog No.:BCC2362
CAS No.:958772-66-2
- (E)-1-(4-Hydroxyphenyl)dec-1-en-3-one
Catalog No.:BCN4031
CAS No.:958631-84-0
- Momordin IIa
Catalog No.:BCN3474
CAS No.:95851-50-6
- Momordin II
Catalog No.:BCN3473
CAS No.:95851-41-5
- Ipsapirone
Catalog No.:BCC7201
CAS No.:95847-70-4
- Hedyotisol B
Catalog No.:BCN4752
CAS No.:95839-45-5
- Piperlotine D
Catalog No.:BCN6494
CAS No.:958296-13-4
- 4-Hydroxyalternariol 9-methyl ether
Catalog No.:BCN7389
CAS No.:959417-17-5
- 5,7,4-Trihydroxy-3,6-dimethoxy-3-prenylflavone
Catalog No.:BCN1297
CAS No.:959421-20-6
- TC-E 5005
Catalog No.:BCC6227
CAS No.:959705-64-7
- Guggulsterone Z
Catalog No.:BCN3793
CAS No.:95975-55-6
- CH5138303
Catalog No.:BCC5364
CAS No.:959763-06-5
- Guajadial
Catalog No.:BCN4509
CAS No.:959860-49-2
- Aminothiazole
Catalog No.:BCC4623
CAS No.:96-50-4
- Mepivacaine
Catalog No.:BCC9020
CAS No.:96-88-8
- 2-hexyl-4-Pentynoic Acid
Catalog No.:BCC6480
CAS No.:96017-59-3
- SD 1008
Catalog No.:BCC2442
CAS No.:960201-81-4
- Vortioxetine (Lu AA21004) HBr
Catalog No.:BCC1213
CAS No.:960203-27-4
- Meropenem
Catalog No.:BCC2489
CAS No.:96036-03-2
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.[Pubmed:17949010]
Biochemistry. 2007 Nov 13;46(45):13019-30.
Fatty acid amide hydrolase (FAAH) is an integral membrane enzyme that degrades the fatty acid amide family of signaling lipids, including the endocannabinoid anandamide. Genetic or pharmacological inactivation of FAAH leads to analgesic, anti-inflammatory, anxiolytic, and antidepressant phenotypes in rodents without showing the undesirable side effects observed with direct cannabinoid receptor agonists, indicating that FAAH may represent an attractive therapeutic target for treatment of pain, inflammation, and other central nervous system disorders. However, the FAAH inhibitors reported to date lack drug-like pharmacokinetic properties and/or selectivity. Herein we describe piperidine/piperazine ureas represented by N-phenyl-4-(quinolin-3-ylmethyl)piperidine-1-carboxamide (PF-750) and N-phenyl-4-(quinolin-2-ylmethyl)piperazine-1-carboxamide (PF-622) as a novel mechanistic class of FAAH inhibitors. PF-750 and PF-622 show higher in vitro potencies than previously established classes of FAAH inhibitors. Rather unexpectedly based on the high chemical stability of the urea functional group, PF-750 and PF-622 were found to inhibit FAAH in a time-dependent manner by covalently modifying the enzyme's active site serine nucleophile. Activity-based proteomic profiling revealed that PF-750 and PF-622 were completely selective for FAAH relative to other mammalian serine hydrolases. We hypothesize that this remarkable specificity derives, at least in part, from FAAH's special ability to function as a C(O)-N bond hydrolase, which distinguishes it from the vast majority of metabolic serine hydrolases in mammals that are restricted to hydrolyzing esters and/or thioesters. The piperidine/piperazine urea may thus represent a privileged chemical scaffold for the synthesis of FAAH inhibitors that display an unprecedented combination of potency and selectivity for use as potential analgesic and anxiolytic/antidepressant agents.
